Topics:

Oncology and Hematology News and Journal Articles

FDA Approves Ramucirumab for Second-Line Treatment of mCRC

The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.

Recent Content

Researchers have shown for the first time that an oncolytic immunotherapy can have therapeutic benefit in patients with advanced melanoma.

A phase III trial found that primary chemotherapy resulted in similar survival compared with primary surgery in newly diagnosed advanced ovarian cancer patients.

In this podcast ahead of the 2015 ASCO Annual Meeting, we discuss CT screening for individuals with a high risk for lung cancer with Claudia I. Henschke, MD, PhD.

Preoperative albumin level and number of extended cytoreductive procedures in ovarian cancer patients predicted the likelihood of surgical complications.

Pancreatic neuroendocrine neoplasm (somatostatinoma)

This slide show features various magnifications of pancreatic neuroendocrine tumors (PNETs) displaying granular cell-like, clear cell, and other features.

The CONCUR trial found that regorafenib improved overall survival in a large group of Asian patients with treatment-refractory metastatic colorectal cancer.

A new study suggests that a family history of breast cancer does not result in a worse prognosis breast cancer prognosis.

By clicking Accept, you agree to become a member of the UBM Medica Community.